Cannabis Policy Updates: Research Legislation, THC Beverages, and Product Recalls

A bipartisan effort is underway to facilitate research into cannabis and other Schedule I substances. Representatives Dina Titus and Ilhan Omar introduced the Evidence-Based Drug Policy Act of 2025 (EBDPA), aiming to remove barriers that currently hinder scientific studies on these substances. The bill seeks to repeal sections of the Office of National Drug Control Policy Reauthorization Act of 1998 that restrict federal funding for research on Schedule I drugs. Advocates argue that this legislation is crucial for understanding the impacts of cannabis use, including health outcomes and social implications, and for informing future policy decisions.

The market for THC-infused drinks is expanding rapidly in the United States, with products now available in various states due to evolving laws and consumer interest. These beverages, often derived from hemp, offer an alternative to traditional alcohol consumption. However, the regulatory landscape remains complex, as federal and state laws differ on the legality and classification of these products. The 2018 Farm Bill legalized hemp-derived products containing less than 0.3% delta-9 THC, but the emergence of synthetic cannabinoids and varying state regulations have created a patchwork of rules that manufacturers and consumers must navigate.

The Arizona Department of Health Services has announced a recall of certain cannabis products after detecting contamination with Aspergillus, a fungus that can pose serious health risks, especially to individuals with weakened immune systems. Consumers are advised to check product labels and consult with healthcare providers if they have used any of the recalled items. This incident underscores the importance of stringent quality control measures in the cannabis industry to ensure consumer safety